Epigenetic Therapeutic Targets Summit, 7/15/2021: Clinical Development of ZEN-3694 in Solid Tumors

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Epigenetic Therapeutic Targets Summit, 7/15/2021: Clinical Development of ZEN-3694 in Solid Tumors

posted on Jul 22, 2021 09:58AM

Eric Campeau of Zenith presented on 7/15/2021 at the Epigenetic Therapeutic Targets Summit on the Clinical Development of ZEN-3694 in solid tumors.

https://www.zenithepigenetics.com/upload/media_element/149/6faaf11603d0/zenith-epigenetic-therapeutic-targets-2021-final.pdf

8 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply